Fingolimod
- PDF / 169,127 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 20 Downloads / 137 Views
1 S
Infections, leukopenia and headache: 4 case reports In a retrospective, multicenter, observational, cohort study of 100 patients with active relapsing remitting multiple sclerosis (RRMS) conducted between March 2018 to December 2018 in Saudi Arabia, 4 patients including a man [ages not stated; not all sexes stated] were described, who developed herpes zoster infection, chest infection, leukopenia or headache during treatment with fingolimod for RRMS [durations of treatments to reactions onsets not stated; not all outcomes stated]. All patients received oral fingolimod 0.5 mg/day. However, fingolimod was stopped as one patient developed severe leukopenia, one patient developed severe headache, one patient developed severe herpes zoster infection, and a man developed severe chest infection that eventually caused his death. Algahtani H, et al. Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience from Saudi Arabia. Clinical Neuropharmacology 43: 35-38, No. 2, Mar 2020. 803497423 Available from: URL: http://doi.org/10.1097/WNF.0000000000000378
0114-9954/20/1818-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 22 Aug 2020 No. 1818
Data Loading...
